Interview with Peter Martin, COO, Norgine
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
Address: 208 Bath Road, Slough, Berkshire, SL1 3WE,United Kingdom
Tel: +44 1 753 534 655
Web: http://www.ucb.com/
A global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of € 3.1 billion in 2009.
Main therapeutic areas:
Immunology
Cimzia® (certolizumab pegol) – Crohn’s disease& Rheumatoid arthritis
Xyzal® (levocetirizine) – Allergies
Zyrtec® (cetirizine) – Allergies
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII) – Respiratory disease
Central Nervous System
Vimpat® (lacosamide) – Epilepsy
Keppra® (levetiracetam) – Epilepsy
Neupro® (rotigotine) – Parkinson’s disease & Restless Legs Syndrome
Nootropil® (piracetam) – Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII) – Attention Deficit Hyperactivity Disorder (ADHD)
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
You used to be the Managing Director of Ranbaxy in China. Having moved to a directorship in the UK, what professional challenges do you see in this country that distinguish…
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Before joining Bristol-Myers Squibb (BMS), you have spent roughly twenty years with GSK. Can you describe the trajectory of your career and explain what attracted you in BMS? Before joining…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business is based in Japan…
This year’s Q1 results for Novo Nordisk were extremely positive with a 23% increase in profit. While this growth was mostly driven by the US and emerging markets, what does…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been…
See our Cookie Privacy Policy Here